A current potential cross-sectional research in Thailand exhibits that multitarget stool DNA testing is extremely delicate and particular for detecting colorectal most cancers (CRC) in Thai people. Researchers consider this testing methodology may function a viable, non-invasive various to colonoscopy, significantly in settings the place colonoscopy is much less accessible or much less accepted by sufferers.
This research was performed in 2023 by BGI Genomics in collaboration with the crew of Professor Varut Lohsiriwat from the School of Medication, Siriraj Hospital, Mahidol College, Thailand. The analysis crew included Professor Varut Lohsiriwat, Dr. Aitsariya Mongkhonsupphawan (MD, Ph.D, School of Medication, Siriraj Hospital, Mahidol College) and Pornraksa Ovartchaiyapong (Lecturer, School of Medication, Siriraj Hospital, Mahidol College). The research was printed in October 2024 in (APJCP).
The researchers targeted on evaluating the diagnostic efficiency of the multitarget stool DNA check for the detection of colorectal most cancers and superior adenoma, utilizing colonoscopy because the reference normal. The research included each asymptomatic and symptomatic sufferers who underwent stool DNA testing and subsequent colonoscopy. The multitarget stool DNA check focused the methylation standing of , and genes. Sensitivity, specificity and different diagnostic parameters had been analyzed.
The research evaluated knowledge from 274 sufferers (common age 62 years, with a predominantly feminine cohort of 60.6%). Colon most cancers was recognized in 17.2% of contributors, whereas superior adenomas, that are precursors to most cancers, had been detected in 6.2%. The multitarget stool DNA check, a non-invasive screening methodology, produced spectacular outcomes: it detected colorectal most cancers with a sensitivity of 91.5% and a specificity of 90.3%, and precisely recognized most cancers in over 90% of instances . The sensitivity of the check was constant for right- and left-sided colon lesions at 92.3% and 91.2%, respectively.
For superior colorectal neoplasms, which embrace each colon most cancers and superior adenomas, the check demonstrated a sensitivity of 75% and a specificity of 91.9%, marking it as a promising instrument for the early detection of significant colorectal ailments. These outcomes spotlight the check’s potential as an efficient screening choice for detecting colorectal most cancers, significantly in bigger lesions, though some limitations stay in detecting smaller abnormalities.
COLOTECT from BGI Genomics® Stool DNA testing kits had been used for pattern and uncooked knowledge assortment. COLOTECT® is a non-invasive colorectal most cancers screening instrument based mostly on DNA methylation testing that targets the methylation profile of colorectal exfoliated cells to estimate the chance of colorectal most cancers and superior adenomas. This system requires no particular gear, has no dietary restrictions, and is utterly non-invasive. In recent times, DNA methylation-based detection of colorectal most cancers has gained traction and has been included into quite a few CRC screening pointers and professional consensus worldwide.
The research outcomes counsel that multitarget stool DNA testing is extremely delicate and particular for CRC detection in Thai people. These exams may present a viable, non-invasive various to colonoscopy, significantly in settings the place colonoscopy is much less accessible or much less accepted by sufferers.
In June 2024, BGI Genomics invited Prof. Varut Lohsiriwat from Mahidol College and Dr. Zhu Shida from BGI Genomics to advance world understanding of CRC and discover methods to shut the attention hole.
Again in 2022, the BGI Genomics Southeast Asia crew fashioned a detailed partnership with Professor Varut Lohsiriwat from the School of Medication, Siriraj Hospital, Mahidol College and invited him to be a part of the BGI Genomics Abroad Science Training Program. On this program, Professor Lohsiriwat shared helpful data and insights on the therapy of colorectal most cancers.
With help from world specialists like Professor Varut’s crew and superior genetic sequencing expertise like BGI Genomics’ COLOTECT® Stool DNA Methylation Check, which extracts DNA from exfoliated intestinal cells in stool samples and detects aberrant methylation in genes related to CRC (, and) Via fluorescence PCR, we anticipate to considerably cut back the world burden of CRC.
Supply:
Journal reference:
Lohsiriwat, V., (2024). Diagnostic accuracy of multitarget stool DNA check for colorectal most cancers screening and detection in Thailand. . doi.org/10.31557/apjcp.2024.25.10.3661.